Data announced at the 61st Annual Meeting of the American Diabetes Association (ADA)
25th June 2001, Philadelphia, USA New study results announced at the ADA demonstrate that AVANDIA (rosiglitazone maleate) may have the potential to reduce cardiovascular risk in patients with Type 2 diabetes due to its beneficial effect on insulin resistance.1-3 AVANDIA, a PPAR (Peroxisome Proliferator-Activated Receptor) gamma agonist (also known as a glitazone or thiazolidinedione) directly targets insulin resistance. Insulin resistance is a fundamental defect of Type 2 diabetes and is associated with a number of cardiovascular risk factors.4 Cardiovascular disease and related events are key medical complications associated with Type 2 diabetes as well as primary cost drivers.5-7
Professor Enzo Bonora from the University of Verona, Italy, said today, "I am extremely encouraged by the results presented at ADA which clearly demonstrate Avandias ability to significantly reduce insulin resistance, and I hope that these data could translate into better cardiovascular outcomes in patients. This is positive news as there are approximately 190 million people worldwide who suffer from Type 2 diabetes and most of them are at high risk of dying from cardiovascular disease."
Professor Bonora reported final results from three trials, involving over 1,000 patients with Type 2 diabetes, which evaluated the effects of AVANDIA on insulin resistance in combination with traditional therapy (sulphonylurea [SU] or metformin [MET]) compared with traditional therapy alone, and as monotherapy compared to glyburide (glibenclamide). In the two 26 week combination trials, statistically significant reductions in insulin resistance were only achieved with AVANDIA plus SU or MET. The results were consistent to the third study, a monotherapy trial which demonstrated a notably significant reduction in insulin resistance with AVANDIA compared with glyburide.